中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

126 records (took 0.032 seconds)

    USE OF ZAPRINAST FOR THE MANUFACTURE OF A MEDICAMENT FOR INHIBITING VASCULAR RESTENOSIS
    31.
    发明申请
    USE OF ZAPRINAST FOR THE MANUFACTURE OF A MEDICAMENT FOR INHIBITING VASCULAR RESTENOSIS 审中-公开
    使用ZAPRINAST制造药物以抑制血管收缩

    公开(公告)号：WO1996011688A1

    公开(公告)日：1996-04-25

    申请号：PCT/US1995012366

    申请日：1995-10-10

    Applicant: WASHINGTON UNIVERSITY ,  GREENWALD, James, E.

    Inventor： WASHINGTON UNIVERSITY

    IPC: A61K31/505

    CPC classification number: A61K31/519

    Abstract: A method is disclosed for treatment of arterial stenosis which comprises administering to a warm-blooded mammal following balloon angioplasty a small but effective amount of zaprinast sufficient to inhibit intimal hyperplasia in said mammal.

    Abstract translation: 公开了一种用于治疗动脉狭窄的方法，其包括在球囊血管成形术之后向温血动物施用足以抑制所述哺乳动物内膜增生的小但有效量的zaprinast。

    METHOD OF INHIBITING TISSUE ISCHEMIA AND REPERFUSION INJURY
    32.
    发明申请
    METHOD OF INHIBITING TISSUE ISCHEMIA AND REPERFUSION INJURY 审中-公开
    抑制组织间质损伤和再灌注损伤的方法

    公开(公告)号：WO1996006637A1

    公开(公告)日：1996-03-07

    申请号：PCT/US1995010626

    申请日：1995-08-24

    Applicant: WASHINGTON UNIVERSITY ,  KOUDSI, Basem ,  WUN, Tze-Chein

    Inventor： WASHINGTON UNIVERSITY

    IPC: A61K38/55

    CPC classification number: A61K38/57

    Abstract: A method for reducing the extent of tissue ischemia and reperfusion injury in a warm-blooded mammal is disclosed which comprises administering by local, regional, or systemic perfusion to the site of a bodily injury subject to interval tissue ischemia in said mammal a small but effective amount of tissue factor pathway inhibitor (TFPI) sufficient to reduce the extent of said tissue ischemia and reperfusion injury.

    Abstract translation: 公开了一种降低温血哺乳动物组织缺血和再灌注损伤程度的方法，其包括通过局部，区域或全身灌注给所述哺乳动物间隔组织缺血的身体损伤部位施用小而有效的方法 组织因子途径抑制剂（TFPI）的量足以减少所述组织缺血和再灌注损伤的程度。

    METHOD OF ATTENUATING ARTERIAL STENOSIS
    34.
    发明申请
    METHOD OF ATTENUATING ARTERIAL STENOSIS 审中-公开
    方法治疗椎间盘突出症

    公开(公告)号：WO1996001649A1

    公开(公告)日：1996-01-25

    申请号：PCT/US1995008221

    申请日：1995-07-06

    Applicant: WASHINGTON UNIVERSITY ,  ABENDSCHEIN, Dana, R.

    Inventor： WASHINGTON UNIVERSITY

    IPC: A61K38/57

    CPC classification number: A61K38/57

    Abstract: A method is disclosed for attenuating stenosis after balloon angioplasty. The method comprises administering parenterally to a subject following balloon angioplasty an effective amount of tissue factor pathway inhibitor (TFPI) sufficient to reduce the extent of restenosis. An exemplary amount of the TFPI is from about 0.5 mg/kg to about 6 mg/kg during a prolonged administration of about three (3) hours to 24 hours.

    Abstract translation: 公开了一种减轻球囊血管成形术后狭窄的方法。 该方法包括在球囊血管成形术之后向受试者肠胃外施用足以减少再狭窄程度的有效量的组织因子途径抑制剂（TFPI）。 在延长施用约三（3）小时至24小时期间，TFPI的示例性量为约0.5mg / kg至约6mg / kg。

    METHODS AND COMPOSITIONS FOR INHIBITION OF HEPATIC CLEARANCE OF TISSUE-TYPE PLASMINOGEN ACTIVATOR
    37.
    发明申请
    METHODS AND COMPOSITIONS FOR INHIBITION OF HEPATIC CLEARANCE OF TISSUE-TYPE PLASMINOGEN ACTIVATOR 审中-公开
    用于抑制组织型PLASMINOGEN激活剂的HEPATIC CLEARANCE的方法和组合物

    公开(公告)号：WO1994014471A1

    公开(公告)日：1994-07-07

    申请号：PCT/US1993012380

    申请日：1993-12-17

    Applicant: WASHINGTON UNIVERSITY

    Inventor： WASHINGTON UNIVERSITY ,  SCHWARTZ, Alan, L. ,  BU, Guojun

    IPC: A61K37/47

    CPC classification number: C07K14/705 ,  A61K38/00 ,  C07K14/47

    Abstract: Methods and compositions for inhibiting the hepatic clearance of tissue-type plasminogen activator (t-PA) in vivo by administering a t-PA-hepatic clearance-inhibiting amount of 39kDa protein or a t-PA-hepatic clearance-inhibiting fragment thereof, or genetically or chemically modified forms of the 39kDa protein or fragments thereof are described. Compositions for treatment of thrombolytic diseases comprised of t-PA and a t-PA-hepatic clearance-inhibiting effective amount of 39kDa protein, a t-PA-hepatic clearance inhibiting fragment thereof, and genetically or chemically modified forms of the 39kDa protein or its fragments are described.

    Abstract translation: 通过施用t-PA-肝清除抑制量的39kDa蛋白质或其t-PA-肝脏清除抑制片段或在其中抑制组织型纤溶酶原激活物（t-PA）的肝脏清除的方法和组合物，或 描述39kDa蛋白或其片段的遗传或化学修饰形式。 用于治疗溶栓性疾病的组合物，其包含t-PA和t-PA-肝清除抑制有效量的39kDa蛋白质，其t-PA-肝脏清除抑制片段，以及遗传或化学修饰形式的39kDa蛋白或其 描述片段。

    TIGHTLY REGULATED EXPRESSION SYSTEM FOR EUCARYOTIC CELLS
    38.
    发明申请
    TIGHTLY REGULATED EXPRESSION SYSTEM FOR EUCARYOTIC CELLS 审中-公开
    用于真核细胞的轻度调节表达系统

    公开(公告)号：WO1993017103A1

    公开(公告)日：1993-09-02

    申请号：PCT/US1993002085

    申请日：1993-02-24

    Applicant: WASHINGTON UNIVERSITY

    Inventor： WASHINGTON UNIVERSITY ,  THACH, Robert, E.

    IPC: C12N15/00

    CPC classification number: C12N15/85 ,  C12N2830/002 ,  C12N2830/50 ,  C12N2830/85 ,  C12N2840/002 ,  C12N2840/105

    Abstract: The invention relates to an expression system which permits control of the levels of protein produced, and optionally provides production of the mature form of the protein directly. The expression systems of the invention include the desired gene downstream of a first DNA which comprises the reverse transcript of the iron-responsive element (IRE) and a second DNA which is the reverse transcript of a portion of the mRNA of an iron-responsive message corresponding to ferritin light chain-derived helping element. These reverse transcripts are operatively linked to a transcriptional promoter which may also be inducible. The expression system is useful, especially, for the production of toxic proteins since protein production can be delayed until desired.

    Abstract translation: 本发明涉及允许控制产生的蛋白质水平的表达系统，并且任选地直接提供成熟形式的蛋白质的产生。 本发明的表达系统包括第一DNA下游所需的基因，其包含铁响应元件（IRE）的逆转录物和作为铁响应信息的mRNA的一部分的逆转录物的第二DNA 对应于铁蛋白轻链衍生的辅助元素。 这些逆转录物可操作地连接到也可诱导的转录启动子。 表达系统特别适用于生产毒性蛋白质，因为蛋白质生产可以延迟至所需。

    POLYNUCLEOTIDE PROBES FOR SALMONELLA
    39.
    发明申请
    POLYNUCLEOTIDE PROBES FOR SALMONELLA 审中-公开
    沙门氏菌的多核苷酸探针

    公开(公告)号：WO1993004202A1

    公开(公告)日：1993-03-04

    申请号：PCT/US1992006984

    申请日：1992-08-19

    Applicant: WASHINGTON UNIVERSITY

    Inventor： WASHINGTON UNIVERSITY ,  GALAN, Jorge ,  CURTISS, Roy, III

    IPC: C12Q01/68

    CPC classification number: C12Q1/689

    Abstract: Polynucleotide probes and primers derived from the Salmonella typhimurium inv genes are described. These polynucleotides can be used as universal probes and primers to detect the presence or absence of Salmonella nucleotide sequences in a biological sample.

    Abstract translation: 描述了源自鼠伤寒沙门氏菌inv基因的多核苷酸探针和引物。 这些多核苷酸可用作通用探针和引物以检测生物样品中沙门氏菌核苷酸序列的存在或不存在。

    HUMAN SUBSTANCE P RECEPTOR
    40.
    发明申请
    HUMAN SUBSTANCE P RECEPTOR 审中-公开
    人体物质受体

    公开(公告)号：WO1993003137A1

    公开(公告)日：1993-02-18

    申请号：PCT/US1992006532

    申请日：1992-08-05

    Applicant: WASHINGTON UNIVERSITY

    Inventor： WASHINGTON UNIVERSITY ,  KRAUSE, James, E.

    IPC: C12N01/20

    CPC classification number: C07K14/70571

    Abstract: The disclosure describes the isolation, characterization and cDNA coding the human substance P receptor, the primary structure of the receptor protein, and a CHO cell line transformed with a DNA expression vector containing a cDNA encoding the human substance P receptor.

    Abstract translation: 本公开描述了人体物质P受体的分离，表征和cDNA编码，受体蛋白质的一级结构以及用含有编码人物质P受体的cDNA的DNA表达载体转化的CHO细胞系。

Patent Agency Ranking